JAGUAR HEALTH INC (JAGX)
US47010C8055 - Common Stock
Overall JAGX gets a fundamental rating of 2 out of 10. We evaluated JAGX against 195 industry peers in the Pharmaceuticals industry. JAGX may be in some trouble as it scores bad on both profitability and health. JAGX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
JAGX had negative earnings in the past year.
In the past year JAGX has reported a negative cash flow from operations.
In the past 5 years JAGX always reported negative net income.
JAGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
JAGX has a worse Return On Assets (-69.19%) than 69.95% of its industry peers.
JAGX has a worse Return On Equity (-264.61%) than 76.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.19% | ||
| ROE | -264.61% | ||
| ROIC | N/A |
ROA(3y)-93.37%
ROA(5y)-98.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 79.07%, JAGX belongs to the top of the industry, outperforming 82.90% of the companies in the same industry.
In the last couple of years the Gross Margin of JAGX has grown nicely.
The Profit Margin and Operating Margin are not available for JAGX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.07% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.75%
GM growth 5Y16.19%
2. Health
2.1 Basic Checks
JAGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
JAGX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, JAGX has less shares outstanding
Compared to 1 year ago, JAGX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -9.15, we must say that JAGX is in the distress zone and has some risk of bankruptcy.
JAGX has a Altman-Z score of -9.15. This is in the lower half of the industry: JAGX underperforms 74.61% of its industry peers.
A Debt/Equity ratio of 1.50 is on the high side and indicates that JAGX has dependencies on debt financing.
With a Debt to Equity ratio value of 1.50, JAGX is not doing good in the industry: 76.68% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.5 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.15 |
ROIC/WACCN/A
WACC5.46%
2.3 Liquidity
JAGX has a Current Ratio of 1.89. This is a normal value and indicates that JAGX is financially healthy and should not expect problems in meeting its short term obligations.
JAGX has a Current ratio of 1.89. This is in the lower half of the industry: JAGX underperforms 66.84% of its industry peers.
JAGX has a Quick Ratio of 1.39. This is a normal value and indicates that JAGX is financially healthy and should not expect problems in meeting its short term obligations.
JAGX has a worse Quick ratio (1.39) than 72.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.39 |
3. Growth
3.1 Past
JAGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.51%, which is quite impressive.
JAGX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.29%.
JAGX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.19% yearly.
EPS 1Y (TTM)94.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.57%
Revenue 1Y (TTM)-10.29%
Revenue growth 3Y1.32%
Revenue growth 5Y17.19%
Sales Q2Q%19.22%
3.2 Future
Based on estimates for the next years, JAGX will show a very strong growth in Earnings Per Share. The EPS will grow by 41.00% on average per year.
JAGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 110.13% yearly.
EPS Next Y98.46%
EPS Next 2Y41%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year62.09%
Revenue Next 2Y55.93%
Revenue Next 3Y139.42%
Revenue Next 5Y110.13%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
JAGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JAGX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as JAGX's earnings are expected to grow with 41.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for JAGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
JAGUAR HEALTH INC
NASDAQ:JAGX (6/14/2024, 7:17:18 PM)
After market: 4 -0.05 (-1.23%)4.05
+0.34 (+9.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap19.80M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.19% | ||
| ROE | -264.61% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.07% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.5 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)94.51%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y98.46%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-10.29%
Revenue growth 3Y1.32%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y